Afuresertib
Afuresertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-alpha serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-gamma serine/threonine-protein kinase.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 8 | 3 | — | — | — | 9 | |
| Castration-resistant prostatic neoplasms | D064129 | 1 | 1 | — | — | — | 1 | ||
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 1 | — | — | — | 1 | |
| Langerhans-cell histiocytosis | D006646 | C96.6 | — | 1 | — | — | — | 1 | |
| Triple negative breast neoplasms | D064726 | 1 | 1 | — | — | — | 1 | ||
| Non-small-cell lung carcinoma | D002289 | 1 | 1 | — | — | — | 1 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | 1 | — | — | — | 1 | |
| Esophageal neoplasms | D004938 | C15 | 1 | 1 | — | — | — | 1 | |
| Uterine cervical neoplasms | D002583 | 1 | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | AFURESERTIB |
| INN | afuresertib |
| Description | N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide is a member of amphetamines. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl |
Identifiers
| PDB | — |
| CAS-ID | 1047634-63-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2219422 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 8739X25QI3 (ChemIDplus, GSRS) |
Target
Agency Approved
AKT1
AKT1
AKT2
AKT2
AKT3
AKT3
Organism
Homo sapiens
Gene name
AKT1
Gene synonyms
PKB, RAC
NCBI Gene ID
Protein name
RAC-alpha serine/threonine-protein kinase
Protein synonyms
AKT1m, PKB, PKB alpha, Protein kinase B, Protein kinase B alpha, Proto-oncogene c-Akt, rac protein kinase alpha, RAC-PK-alpha, serine-threonine protein kinase, v-akt murine thymoma viral oncogene homolog 1, v-akt murine thymoma viral oncogene-like protein 1
Uniprot ID
Mouse ortholog
Akt1 (11651)
RAC-alpha serine/threonine-protein kinase (P31750)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 296 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more